Nuvation Bio Inc（NUVB）股票分析NUVBNuvation Bio Inc

Nuvation Bio Inc. is a global oncology company. The Company is focused on tackling cancer treatment. Its diverse pipeline includes taletrectinib (IBTROZI), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor, and a drug-drug conjugate (DDC) program. IBTROZI is an oral, potent, central nervous system-active, selective, next-generation ROS1 inhibitor. Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1), which is detected in various tumors, including gliomas. Its platform leverages its drug discovery and chemistry expertise to find the minimum target binding sites of drug X and drug Y and fuse them together, while maintaining activity. Its DDCs are designed to selectively bind to intracellular as well as surface cell membrane targets that are expressed more highly in specific target tissues and to potently deliver anti-cancer warheads to these target tissues. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nuvation Bio Inc. is a good buy right now due to its current price of $4.57, which is significantly below the analyst consensus target of $13.36, indicating a potential upside of 137.76%. Additionally, the company has shown a strong gross margin of 92.80% in Q1 2026, reflecting its profitability potential. The main risk is the negative earnings per share (EPS) forecast of -0.12 for the upcoming earnings report on November 4, 2026, which could impact short-term sentiment.